Surprisingly, we found that the multi-biomarker panel (7MP) combining the conventional markers NSE, squamous cell carcinoma antigen (SCC), pro-gastrin-releasing peptide (Pro-GRP), and 4MP could significantly improve the performance of 4MP in differentiated LADC, SQCLC, and SCLC, which may contribute to achieving personalized precision treatment. This evidence concerns the gene GRP and small cell lung carcinoma.